Timmis A D, Campbell S, Monaghan M J, Walker L, Jewitt D E
Br Heart J. 1984 Apr;51(4):445-51. doi: 10.1136/hrt.51.4.445.
Felodipine is a new calcium antagonist with a high degree of vascular selectivity. To examine its potential value as an afterload reducing agent in congestive heart failure 11 patients were studied. Substantial increments in cardiac index were associated with a fall in systemic vascular resistance. Left ventricular end diastolic pressure was also significantly reduced. Although left ventricular maximum dP/dt remained unchanged, maximum dP/dt/P increased. Left ventricular unloading was reflected by a reduction in cavity dimensions and a shift in the relation between end systolic pressure and dimension downwards and to the left. The myocardial oxygen supply to demand ratio was also improved: coronary sinus flow increased significantly despite a decline in myocardial oxygen consumption. These beneficial haemodynamic and metabolic effects suggest that felodipine may extend the clinical application of calcium antagonists to include the treatment of congestive heart failure.
非洛地平是一种具有高度血管选择性的新型钙拮抗剂。为研究其作为充血性心力衰竭后负荷降低剂的潜在价值，对11例患者进行了研究。心指数显著增加与全身血管阻力下降相关。左心室舒张末期压力也显著降低。尽管左心室最大dp/dt保持不变，但最大dp/dt/P增加。左心室负荷减轻表现为腔室尺寸减小以及收缩末期压力与尺寸之间的关系向左下方移位。心肌氧供需比也得到改善：尽管心肌耗氧量下降，但冠状窦血流量显著增加。这些有益的血流动力学和代谢效应表明，非洛地平可能会扩大钙拮抗剂的临床应用范围，使其包括充血性心力衰竭的治疗。
